When should surgical cytoreduction in advanced ovarian cancer take place?

Martinek, Igor E; Kehoe, Sean

DOI: 10.1155/2010/852028

License: Creative Commons: Attribution (CC BY)

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 21. Dec. 2018
Review Article

When Should Surgical Cytoreduction in Advanced Ovarian Cancer Take Place?

Igor E. Martinek and Sean Kehoe

Oxford Gynaecological Cancer Centre Surgery and Diagnostics, Level 0, Churchill Hospital, Oxford OX3 7JL, UK

Correspondence should be addressed to Igor E. Martinek, igor.martinek@bluewin.ch

Received 29 April 2009; Accepted 13 September 2009

1. Introduction

Ovarian cancer represents the sixth most commonly diagnosed cancer among women in the world and causes more deaths per year than any other cancer of the female reproductive system [1]. In advanced disease which constitutes about 75% of women at presentation, the accepted management is a combination of surgery and platinum based chemotherapy. This has been the approach for some decades, though the 5-year survival remains poor at about 40%. Epithelial ovarian cancer constitutes the majority of disease types, and this review will focus on reports relating to advanced epithelial ovarian carcinoma.

2. Materials and Methods

A Medline database search (January 1966 to April 2009) was undertaken using key words: epithelial ovarian cancer, debulking surgery, and interval debulking surgery resulting in 80 articles with 14 relevant papers. The articles in full were obtained for each of the papers and reviewed by the authors. Results in terms of overall survival (OS) and progression free survival (PFS) were evaluated in each study.

3. Results

The 80 resulting articles were screened and 14 relevant papers were retained: 3 meta-analysis [2–4], 3 randomized control trials (RTC) [5–7] (Table 1) 2 Cochrane Reviews (CRs) [8, 9], and 6 case/control (CC) reports enrolling more than 50 patients [10–15] (Table 2).

4. Discussion

4.1. Primary Debulking Surgery. The initial studies supporting the concept of debulking surgery were published in the
1970s by Griffiths et al. [16]. The premise for considering the potential impact of reducing intra-abdominal tumour burden was based on the findings of work by Magrath et al. [17], which reported enhanced survival outcome by reducing intra-abdominal disease, in patients with Hodgkin’s disease. Griffiths undertook a retrospective analysis of just over 100 women and noted that those with residual disease masses <1.6 cms in largest diameter had an improved survival outcome compared with patients left with a greater disease volume. A subsequent small prospective study [18] on a heterogeneous population of patients, who underwent aggressive radical surgery, also revealed the better survival pattern associated with less tumour burden. Thus, the concept of debulking surgery in ovarian cancer became the normal approach to this disease. The use of adjuvant chemotherapy, which is platinum based, is also the accepted norm in care. The question as to whether the surgical ability of the operator or the inherent tumour biology of the disease is the main factor impacting on survival remains a debate. Indeed, the benefit of radical debulking has already come under criticism [19] while some have advocated that tumour biology rather than the surgical effort might determine prognosis [20]. In a study of 213 patients with Stage IIIIC epithelial ovarian cancer who underwent complete cytoreduction before initiation of systemic platinum-based combination chemotherapy, Eisenkop and Spiratos [21] came to the conclusion that the need to remove a large number of peritoneal implants correlates with biological aggressiveness and diminished survival, but not significantly enough to preclude long-term survival or justify abbreviation of the operative effort.

Regarding primary surgery, there is a plethora of published papers, all of which support the findings of Griffiths, though none are randomized controlled trials, and hence, all with similar inherent biases. It is also important to note that various definitions of optimal cytoreduction have been proposed [22–24]. The Gynaecologic Oncology Group (GOG) currently defines optimal cytoreduction as leaving residual disease less than 1 cm in maximum tumour diameter. Some may argue that optimum should only mean no macroscopic residual disease.

There are 3 systematic reviews on residual disease and outcome, which have conflicting conclusions. In an analysis of 81 cohorts of patients (over 6000 women) with advanced-stage ovarian carcinoma treated with platinum-based chemotherapy Bristow et al. [4] found a 5.5-percent increase in median survival for every 10-percent increase in the proportion of patients achieving maximal cytoreduction. Contrary to these findings was the meta-analysis by Hunter et al. [2], (again over 6000 women) whereby the administration of platinum was deemed more important in influencing survival rather than the achievement of optimum debulking surgery. The main difference between these papers is that in Bristow’s study, all patients were exposed to adjuvant platinum therapy, which was not the case in Hunters study. The third and smaller study also concluded that optimum debulking was associated with improved survival patterns, though further prospective trials were necessary [3].

4.2. Secondary Surgical Cytoreduction. At the beginning of the eighties, Berek et al. [25] noticed that secondary cytoreduction could also improve survival. Subsequently, the role of interval debulking surgery (IDS) has been investigated in three prospective Randomized Controlled Trials (RCTs) [5–7] where conclusions are different. Interval debulking surgery is defined as a second operation performed after 3 or 4 cycles of platinum chemotherapy in woman who had

### Table 1: RCTs investigating the role of IDS.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>550 with 448 randomized 226 IDS versus 222 no IDS</td>
<td>425 with 319 randomized 278 evaluated: 138 IDS versus 140 no IDS</td>
<td>86 randomized with 7 excluded&lt;sup&gt;+&lt;/sup&gt; 37 IDS42 no IDS</td>
</tr>
<tr>
<td>FIGO stage</td>
<td>II-IV</td>
<td>IIB-IV</td>
<td>II-IV</td>
</tr>
<tr>
<td>Trial characteristics</td>
<td>RD &gt; 1 cm after primary surgery and responding/stable after 3 cycles of Cisplatin/pacitaxel Stage IV only pleural effusion</td>
<td>RD &gt; 1 cm &amp; maximum primary debulking not attempted in all cases with high proportion of RD &gt;5 cm Randomization after 3 cycles of CP</td>
<td>Primary surgery and RD &gt; 2 cm 1–4 CP Or 3 PAB followed by 5&lt;sup&gt;+&lt;/sup&gt; escalating CP</td>
</tr>
<tr>
<td>PFS for IDS versus No IDS</td>
<td>12.5 versus 12.7</td>
<td>18 versus 13</td>
<td>15 versus 12 months</td>
</tr>
<tr>
<td>OS for IDS versus No IDS</td>
<td>36.2 versus 35.7</td>
<td>26 versus 20</td>
<td></td>
</tr>
</tbody>
</table>
suboptimal debulking primary surgery. Table 1 summarizes the main features of these trials.

The trials by Redman et al. [7] and the GOG by Rose et al. [6] failed to show any advantage of IDS. The study by Redman was closed prematurely, as no survival benefit was noted at interim analysis, and of note, optimum debulking was defined as <2 cms residuum compared with <1 cms in the other studies. In the GOG study, 550 women with suboptimally debulked stage III/IV ovarian cancer received three cycles of paclitaxel/cisplatin and then were randomly assigned to interval cytoreduction or no surgery. Chemotherapy was continued up to a maximum of 6 cycles. A secondary attempt at cytoreduction was not associated with an improvement in progression free survival (PFS) (12.5 versus 12.7 months) or overall survival (OS) (36.2 versus 35.7 months). This was not the case with the EORTC trial carried out by Van de Burg et al. [5], which showed that the IDS group had a significantly increased median survival of 6 months compared to those who had not undergone this procedure. Indeed this is still the only prospective RCT showing a survival benefit with “debulking” surgery. Nevertheless, it is important to point out some differences between these trials. At the time of the EORTC trial, chemotherapy consisted of cisplatin/cyclophosphamide as Paclitaxel was not available, unlike the GOG trial. Another major difference was that in the EORTC trial, primary surgery was not necessarily performed by a trained gynaecological oncologist, resulting in different extents of debulking. The number of patients with less than 5 cm of residual tumour following primary cytoreduction in the EORTC trial was less than a third, compared to 55 percent in the GOG trial. Surgery performed by a trained gynaecological oncologist has been shown to increase progression free survival (PFS) (12.5 months) compared to those who had not undergone this procedure. The EORTC trial showed a significant increase in OS of 39 months versus 26 months, and despite a response to NACT in 90% of cases, there was no long-term survivors in the patients whose interval cytoreduction was suboptimal. Generally, OS was stated to be influenced by three main factors: the extent of the disease at the time of diagnosis, the biology of the disease, and patient performance status; TFI: treatment free interval.

### 4.3. Neoadjuvant Chemotherapy (NACT) and Debulking Surgery

The term IDS should be confined to patients who have had primary surgical debulking, but it has been used in situations whereby a primary surgical attempt is delayed until during chemotherapy. Six large case-control studies [10–15] relating to “delayed” primary surgery were identified, and are summarized in Table 2.

One of the studies [10, Colombo et al.] divided patients into 2 groups to evaluate the place of surgery in the therapeutic sequence of care: group 1 receiving upfront surgery and group 2 where first debulking was undertaken after chemotherapy. In group 1 the OS was 38 months and 3 factors significantly predicted suboptimal upfront surgery: poor performance status, extensive mesenteric involvement, and stage IV disease. The second group showed OS of 26 months, and despite a response to NACT in 90% of cases, there was no long-term survivors in the patients whose interval cytoreduction was suboptimal. Generally, OS was stated to be influenced by three main factors: the extent of the disease at the time of diagnosis, the biology of the disease, and patient performance status; TFI: treatment free interval.

### Table 2: Nonrandomized case control studies evaluating delayed primary debulking surgery.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>203</td>
<td>789 (217 IDS 572 non IDS)</td>
<td>59 all submitted to prior surgical exploration</td>
<td>61</td>
<td>109</td>
<td>285</td>
</tr>
<tr>
<td>FIGO stage</td>
<td>IIc-IV</td>
<td>All stages treated for 1st relapse</td>
<td>II-IV</td>
<td>IV without bowel obstruction</td>
<td>IV</td>
<td>III-IV</td>
</tr>
<tr>
<td>Important study data</td>
<td>Gr 1 conventional OS = 38 m Gr 2 with NACT OS = 26 m</td>
<td>Platinum single or combination/taxol single or combination or other</td>
<td>N = 27 (OS = 25 m) unresectable NACT with 18 for IDSN = 32 primary cytoreduction (OS = 28)</td>
<td>NACT platinum-taxol OS = 41.7 m</td>
<td>NACT platinum-taxol + IDSN = 45.5 m (under 20% of patients in study)</td>
<td>Choice of treatment: upfront surgery or NACT according to disease extent and patient PPS</td>
</tr>
<tr>
<td>Main conclusions</td>
<td>Upfront surgery for advanced operable disease</td>
<td>Benefit of IDS versus chemotherapy alone when tumour is localised.</td>
<td>NACT for unresectable tumours leads to a group of sensitive patients for successful IDS</td>
<td>Response rate to NACT comparable to that of upfront surgery stated in literature</td>
<td>Benefit of IDS in patient responding to NACT</td>
<td>OS was higher for patients with high tumour load treated with NACT than with upfront surgery</td>
</tr>
<tr>
<td></td>
<td>NACT for non operable or poor performance status with IDS ideally after 3 cycles</td>
<td>Best OS (48 m) with radical primary cytoreduction, TFI &gt;24 m &amp; ≤ 39 years</td>
<td>Importance of maximal secondary cytoreduction in IDS</td>
<td>NACT can select patients for surgery</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IDS: interval debulking surgery; m = months; NACT: neoadjuvant chemotherapy; OS: overall survival; PFS: progression free survival; PPS: patient performance status; TFI: treatment free interval.
tumour, and its chemosensitivity, and the authors concluded that optimal surgery with limited morbidity (14% in their case) can be achieved in many cases at primary surgery setting. Hegazy et al. [12] found, in a population of patients with advanced ovarian carcinoma where resectability was not possible, that neoadjuvant chemotherapy helped to select patients for feasible and relatively less aggressive IDS, thus preventing initial surgical failure, in terms of optimal debulking. However, Morris et al. [27] in 1989 demonstrated that patients resistant to chemotherapy during primary treatment had little benefit from IDS. This was also concluded by Rafii et al. [14] as well as the selection effect of NACT for the second intention surgery.

In another recent study [13], the complete response rates after three cycles of platinum/taxane chemotherapy was 36.1%. After IDS, 80% of all patients were left with optimal residuals (<2 cms). The response rate to chemotherapy given in a neoadjuvant setting was comparable to those published in literature in patients who were treated with conventional upfront tumour reduction surgery followed by adjuvant chemotherapy. They also found that residual decease after IDS is the only significant predictive factor associated with prolonged PFS ($P = .003$). To date, there is very little good quality evidence to either support or refute the use of neoadjuvant chemotherapy in the treatment of ovarian cancer [9].

A retrospective study between 1980 and 1997 from Vergote et al. [15] included 285 patients with stages III and IV ovarian cancer. In the period from 1980 to 1988, optimal primary cytoreduction (0.5 cm residual disease) was achieved in 82% of cases, but patients with stage IV disease or a metastatic tumour load of >1 kg prior to this procedure had poorer survival with high postoperative mortality (6%). Between 1989 and 1997 patients received either upfront surgery or chemotherapy depending on the extent of the disease and the performance status. This subsequent management improved overall survival, despite a reduction of 25% in the rate of primary debulking.

4.4. Surgery at Relapsed Disease. A large Norwegian retrospective study ($n = 789$) [11] carried out at the Radium Hospital looked at treatment model for 1st relapse of ovarian cancer of any stage. They found that treatment free interval (TFI) following primary therapy is a significant prognostic factor for OS in multivariate analysis. They also report age as prognostic factor for OS at the time of secondary cytoreductive surgery. Survival benefit was clear for patients with optimum secondary cytoreductive surgery followed by chemotherapy compared with chemotherapy alone at the time of recurrence. Complete secondary cytoreductive surgery was found possible in a significant percentage of patients properly selected for this secondary surgery. Localised tumour was found to be a significant factor to predict this optimum surgery. This selection of patients for secondary cytoreductive surgery is thus crucial. Guidelines at relapse [11] for local and disseminated disease have been set up, where secondary cytoreductive surgery is recommended as independent of TFI for localized tumours and should be considered for $\text{TFI} > 24$ months in case of disseminated disease (Table 3).

Selecting the right patients for the right treatment sequence is challenging. Predicting the possibility to perform successful surgery has been studied [28, 29] with one model having an 85% specificity or ability to identify patients undergoing optimal surgery [30]. In certain situations laparoscopy is recommended as the most valuable tool for evaluating the operability in upfront or second line debulking surgery [31].

5. Conclusions

This paper has reviewed only RCTs and large series, which do reflect the findings of many other reports on the specific debates surrounding the role and timing of surgery in ovarian carcinoma. There is agreement that one of the most important prognostic factors for survival in the treatment of ovarian cancer is the amount of residual tumour after cytoreduction [4, 16]. It is welcome to note that in more recent times surgical approaches have undergone scrutiny in RCTs. Indeed there is evidence of a shift from debulking for all to debulking for a select group, or put another way increased individualisation of therapy. Unlike in previous decades the use of neoadjuvant chemotherapy seems to have gained some popularity, though the real impact requires the formal publication of the randomized trials EORTC 55971 and CHORUS. The EORTC study has been presented at the IGCS in Bangkok and generated a lot of debate, as to the role of neoadjuvant chemotherapy. The finalised peer-reviewed publication is awaited with interest.

Another factor which cannot be ignored in the debate is the inherent tumour biology where the question, raised by some [32] and still requiring an answer, is to know if it is the surgeon's skills or tumour biology which determines survival outcome. In this respect, opinions vary regarding its impact on the ability to surgically debulk [21]. On the other hand, others have put forward the strong expression of the p53 tumour suppressor gene correlating with reduced likelihood of achieving complete cytoreduction [33]. The progress and accessibility to novel technologies applied to biology will make possible in the future the assessment of new prognostic profiles based on genetic and/or proteomic tumour characteristics. The future also relies on the identification of predictive factors of response to treatment [34].

<table>
<thead>
<tr>
<th>TFI, months</th>
<th>Local disease</th>
<th>Disseminated disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–5</td>
<td>Consider SCR</td>
<td>No SCR</td>
</tr>
<tr>
<td>6–11</td>
<td>Offer SCR</td>
<td>No SCR</td>
</tr>
<tr>
<td>12–23</td>
<td>Offer SCR</td>
<td>No SCR</td>
</tr>
<tr>
<td>&gt;24</td>
<td>Offer SCR</td>
<td>Consider SCR</td>
</tr>
</tbody>
</table>

SCR: secondary cytoreduction; TFI: treatment-free interval.
References


